Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ipilimumab and Nivolumab in Combination With Immunoembolization for the Treatment of Metastatic Uveal Melanoma

NCT03472586 is registered in ClinicalTrials.gov with Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University as lead sponsor.

NCT NCT03472586
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03472586 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ipilimumab and Nivolumab in Combination With Immunoembolization for the Treatment of Metastatic Uveal Melanoma
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase
Phase 2
Overall status
Completed
Start date
May 2, 2018
Completion date
December 31, 2024
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic malignant neoplasm in the liver, metastatic uveal melanoma, stage iv uveal melanoma ajcc v7